Skip to main content
Premium Trial:

Request an Annual Quote

Philips and Organon Will Use Imaging Technology in Biomarker Research

NEW YORK (GenomeWeb News) — Philips Life Sciences and Organon will perform biomarker studies that could benefit Philips’ imaging programs and Organon's drug-development efforts, the companies said yesterday.
Under the agreement, researchers from both companies will use Philips' labs and medical-imaging technologies to identify, validate, and pursue uses for novel biomarkers that Organon may use to develop drug programs for psychiatric and immune system disorders.
The companies said the research will be conducted at Philips' High Tech Campus in Eindhoven, the Netherlands.
Rick Harwig, Philips’ chief technology officer, said his company's imaging modalities are improving "to image the function and behavior of an anatomical feature, and not just its shape."
Harwig said working with Organon will help Philips "speed the evolution" of its imaging technology "into tools to image the body at the molecular level."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.